Document is current
Any future updates will be listed below
-
Authors
Veltkamp, Roland https://orcid.org/0000-0002-0583-1300
Haas, Kirsten
Rücker, Viktoria
Malzahn, Uwe
Heeger, Adrian
Kinzler, David
Müller, Patrick
Rappard, Pascal
Rizos, Timolaos
Schiefer, Johannes
Opherk, Christian
Pfeilschifter, Waltraud
Althaus, Katharina
Schellinger, Peter
Gaida, Bernadette
Gabriel, Maria Magdalena
Royl, Georg
Nabavi, Darius G.
Haeusler, Karl Georg
Nolte, Christian H.
Wolf, Marc E.
Poli, Sven
Sieber, Marilen
Mosimann, Pascal
Heuschmann, Peter U.
Purrucker, Jan C.
,
Horstmann, Solveig
Krauß, Alexandra
Renninger, Caroline
Ringleb, Peter
Reich, Arno
Kohler, Eve
Boss, Erendira
Schaefer, Jan Hendrik
Pflug, Marc
von Sarnowski, Bettina
Große, Gerrit Maximilian
Ernst, Johanna
Weißenborn, Karin
Schupper, Ramona
Worthmann, Hans
Riebau, Susanne
Crome, Olaf
Dimitrijeski, Boris
Offermann, Jens
Rangus, Ida
Schmid, Elisabeth
Poli, Khouloud
Tünnerhoff, Johannes
Michalski, Dominik
Pelz, Johann O.
Juenemann, Martin
Müller, Tobias BraunTobias J.
Wartenberg, Katja
Binder, Andreas
Meyne, Johannes
Ikenberg, Benno
Härtl, Johanna
Ohms, Michael
Edelbusch, Sebasitan
Fatar, Marc
Alonso, Angelika
Nückel, Martin
Erbguth, Frank
Grau, Alexandra
Selig, Udo
Dziewas, Rainer
Minnerup, Jens
Barlinn, Kristian
Haase, Kathrin
Thomalla, Götz
Deb-Chatterji, Milani
Mäurer, Mathias
Pfau, Mathias
Michels, Peter
Vukovic, Zoran
Uphaus, Timo
Gröschel, Klaus
Gröschel, Sonja
Hahn, Marianne
Mühler, Joannes
Dötter, Klaus
Wagner-Heck, Michaela
Wollenweber, Frank Arne
Jander, Sebastian
Lee, John-Ih
Schäbitz, Wolf-Rüdiger
Piehl, Inken
Frattner, Michael
Staykov, Dimitre
Urbanek, Christian
Schröder, Sabine
Düllberg-Boden, Sylke
Kermer, Pawel
Kaste, Matthias
Marquardt, Lars
Kazarians, Haiko
Kleinschnitz, Christoph
Kraft, Peter
Hoffmann, Frank
Kraft, Andrea
Faiss, Jürgen Hartmut
Reimann, Gernot
Schwarz, Michael
Steiner, Thorsten
Günther, Albrecht
Lamadé, Uta Meyding
Lorenz, Matthias W.
-
Funding
Funding for this research was provided by:
Bayer Vital
Bristol-Myers Squibb and Pfizer Alliance
Boehringer Ingelheim
Daiichi Sankyo Europe
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 6 September 2024
Accepted: 10 November 2024
First Online: 12 February 2025
Declarations
:
: The ethics committee of the Medical Faculty of the University Heidelberg as well as all local ethics committees approved the study protocol (S-088/2015). Patients were eligible for the study if they were 18 years or older and either the patient or a legal representative had provided consent. Informed consent could be waived if patients were not able to consent and died before a legal representative could be installed.
: Not applicable.
: RV is an investigator of the NIHR Imperial Biomedical Research Centre and reports fees for consulting and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Daichi Sankyo, Portola, Biogen, Medtronic, and Morphosys; and research grants from Bayer, Boehringer, Bristol Myers Squibb, Pfizer, Daiichi Sankyo, and Medtronic (ODEA study), outside of the submitted work. TR received consulting honoraria, speakers’ honoraria and travel support from BMS Pfizer, Boehringer Ingelheim, Bayer HealthCare and Daiichi Sankyo, outside the submitted work. WP received consulting honoraria, speakers’ honoraria and travel support from Alexion, Boehringer Ingelheim, Bayer HealthCare and Daiichi Sankyo, outside the submitted work. KA has received lecture fees from Boehringer Ingelheim, Daiichi Sankyo, Alexion and BMS/Pfizer, outside the submitted work. PS received honoraria from Astra Zeneca, Boehringer Ingelheim, Biogen, Daiichi, Amgen, Merck and participated on advisory boards for Boehringer Ingelheim and Astra Zeneca. BG has received speaking honoraria and travel expenses from Bayer Vital GmbH, Boehringer Ingelheim Pharma GmbH & Co.KG, Daiichi Sankyo Deutschland GmbH, UCB Pharma GmbH, UNEEG medical DE GmbH and BMS/Pfizer Alliance, outside the submitted work. GR has received consultation fees and travel expenses from Bayer, Boehringer Ingelheim, Daiichi Sankyo, BMS/Pfizer, Astra Zeneca, Novartis and Cardinal Health, outside the submitted work. DGN has received speaker honoraria, consultation fees and travel expenses from Astra Zeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Sanofi, outside the submitted work. KGH reports speaker´s honoraria, consulting fees, lecture honoraria and/or study grants from Abbott, Alexion, Amarin, AstraZeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medronic, Novartis, Pfizer, Portola, Premier Research, Sanofi, SUN Pharma, and W.L. Gore and Associates. CHN received research grants from the German Ministry of Research and Education, German Center for Neurodegenerative Diseases, German Center for Cardiovascular Research, and speaker and/or consultation fees from Abbott, Alexion, Astra Zeneca, Bayer Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Pfizer Pharma, Portola and Takeda, all outside the submitted work. MEW has received honoraria for lectures from Daiichi Sankyo, BMS/Pfizer and Sanofi. SP has received research support from BMS/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, and German Federal Ministry of Education and Research, Helena Laboratories and Werfen as well as speakers’ honoraria/consulting fees from Alexion, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen (all outside the submitted work). PUH reports grants from the German Ministry of Research and Education, European Union, German Parkinson Society, University Hospital Würzburg, the German Heart Foundation, Federal Joint Committee within the Innovationfond, German Research Foundation, Bavarian State, German Cancer Aid, Charité–Universitätsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), Bristol-Myers Squibb, Boehringer-Ingelheim, and Daiichi Sankyo), outside the submitted work. JP has received consultation fees and travel expenses from Abbott, Akcea, Bayer, Boehringer Ingelheim, Daiichi Sankyo, and BMS/Pfizer, outside the submitted work. All other authors: none.
